LATEST
Cencora agreed to acquire American Oncology NetworknewAPEX / KorainewSmith & Wesson Brands agreed to acquire Long Range IntermediatenewBose acquired SkullcandyMaximus Federal Services agreed to acquire Agile DefenseMount Logan Management agreed to acquire Alternative Fund AdvisorsDime Commercial Bancshares / ES BancsharesSalesforce agreed to acquire BrazeJV Investors / Oro Mobility HoldingsMorgan Stanley Capital Partners acquired The Rapid GroupCBRE Group agreed to acquire Onnec GroupBevPoint Capital agreed to acquire ESG
Open App
ClosedPublished 22 Nov 2022

XOMA (US) LLC /
ObsEva

XOMA (US) LLC acquires ebopiprant rights from ObsEva, SA

Price
$15m
Stage
Closed
Buy side: XOMA (US) LLC
Buy sideXOMA (US) LLC
Target: ObsEva
TargetObsEva
Source · 22 Nov 2022
See the source
Buy side: XOMA (US) LLC
Buy sideXOMA (US) LLC
Target: ObsEva
TargetObsEva
01 / BuyerXOMA (US) LLC
02 / TargetObsEva
01

What happened

XOMA (US) LLC, a wholly-owned subsidiary of XOMA Corporation, acquired all rights and title to ebopiprant, an investigational compound previously licensed by ObsEva, SA.

The agreement provides for $15 million in cash at closing, plus certain earn-out payments based on sales and non-sales milestones.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

XOMA (US) LLC acquires ebopiprant rights from ObsEva, SA

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.